Clinical Chemistry 51, No. 7, 2005 not been established which B 6 vitamer(s) should be used as indicator of B 6 status (5 ), but several indices have been suggested, including plasma PLP (6, 7 ) , the combinations plasma PLP and PL (8 ) , or plasma PLP plus PA (5, 9, 10 ) .
Riboflavin serves as a precursor for flavin mononucleotide (FMN) and FAD (11 ) . These coenzymes are involved in numerous reduction-oxidation reactions and take part in the metabolism of other vitamins, e.g., vitamin B 6 and folate ( Fig. S-1 of the online Data Supplement). Plasma riboflavin appears to be a better indicator of vitamin B 2 status than are plasma FMN and FAD (12 ) .
Measurement of vitamins B 6 and B 2 has become important for the assessment of homocysteine status (2 ) . Overt vitamin B 6 deficiency is regarded as uncommon (6 ) , but marginal deficiency may be related to an increased risk of cardiovascular disease (13, 14 ) . Vitamin B 2 deficiency may be more common than previously recognized, particularly in developing countries (15) (16) (17) , among the elderly, in children, and in women during pregnancy (11 ) .
Several methods for the determination of various B 6 vitamers in human plasma or serum have been developed (9, 18 -29 ) , but at present no rapid and simple method exists for the determination of all 7 forms of vitamin B 6 . Vitamin B 6 methods are usually based on HPLC with fluorescence detection, which requires derivatization of PLP and complete chromatographic separation of the analytes. This often gives relatively long analysis times of ϳ30 min or longer (18, 19, 23, (25) (26) (27) . In studies involving vitamin B 6 in plasma, usually only PLP was determined (20, 30 -34 ) , but in some cases (5, 10, 29, 35, 36 ) , several B 6 vitamers were measured.
Analytical techniques for the determination of vitamin B 2 concentrations include fluorometric (37 ) , liquid chromatographic (38, 39 ) , and capillary electrophoretic methods (40 ) . Most HPLC methods have been designed for the detection of high concentrations of vitamin B 2 in food, pharmaceutical preparations, and urine (38 ) . Some methods have been used for measurement of B 2 in whole blood (41) (42) (43) (44) , serum (42, 43, 45 ) , or plasma (39, 40, 46 -48 ) .
We here describe a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous measurement of 7 vitamin B 6 species and 3 vitamin B 2 species in 60 L of plasma. The assay is sufficiently sensitive to quantify nanomolar concentrations of these vitamers.
Materials and Methods materials
PL hydrochloride (99%), PLP (98%), PN hydrochloride (Ͼ99%), PM dihydrochloride (98%), PA (Ͼ99%), riboflavin (Ͼ98%), FMN (sodium salt; ϳ95%), and FAD (disodium dihydrate salt; Ͼ95%) were purchased from SigmaAldrich. PMP (98%) and heptafluorobutyric acid (HFBA; 99.5%) were purchased from Fluka, and PNP was kindly supplied as a gift from C.J. Argoudelis A series 1100 HPLC system (Agilent Technologies) equipped with a thermostated autosampler and a degasser was used for solvent delivery and sample introduction. The HPLC system was coupled to an API 4000 triple-quadrupole tandem mass spectrometer (Applied Biosystems/MDS SCIEX) outfitted with an electrospray ion source. A column switcher from Valco (type VMHA) was used to divert the flow to waste during the first 2.0 min and the last 2.2 min of the run. Analyst (Ver. 1.3.1; Applied Biosystems/MDS SCIEX) was used for data acquisition and analysis.
lc-ms/ms
We injected 50 L of deproteinized plasma into an Agilent stable-bond C 8 reversed-phase column [150 ϫ 4.6 (i.d.) mm; particle size, 3.5 m] equipped with an Agilent stable-bond C 8 guard column [12.5 ϫ 4.6 (i.d.) mm; particle size, 5 m]. The guard and analytical columns were mounted in a thermostated column compartment set at 20°C. The flow rate was 1 mL/min.
The mobile phase consisted of 3 components, solution A (650 mmol/L acetic acid), solution B (100 mmol/L HFBA in A), and solution C (900 mL/L acetonitrile in water).
The column was developed with gradient elution according to the following timetable: 0 -0.2 min (97.5% A and 2.5% B), 6 min (28% A, 2.5% B, and 69.5% C), 6.1-6.6 min (2.5% B and 97.5% C), 6.7-8 min (97.5% A and 2.5% B). All gradient steps were linear.
Samples were injected every 8.75 min. The column effluent was delivered to the mass spectrometer with no split.
Acquisition settings were optimized by infusion of a 10 mol/L solution of each vitamer at a rate of 1 L/min.
Before entering the mass spectrometer, this solution was mixed at a T-junction with mobile phase delivered at a rate of 1 mL/min and with a composition corresponding to the time of elution of the actual analyte. The optimized conditions were adjusted according to 3 scan segments to acquire a sufficient signal quality, which is related to the number of data points across each chromatographic peak. The settings are detailed in Table 1 . Curtain gas (10 psig), collision gas (4 psig), ion source temperature (490°C), ion source gases 1 and 2 (10 psig), and activated interface heater were identical for all segments.
The mass spectrometer was operated in the positiveion mode. The vitamers were detected in the multiplereaction monitoring (MRM) mode with unit resolution at both Q1 and Q3. The ion transitions for all analytes are shown in Table 1 , which lists the protonated molecular ion [MϩH] ϩ and the dominant product ion. Table 1 
assessment of matrix effects
We investigated the matrix effects (49 ) , which can be observed as ion enhancement or ion suppression (50 ) , in plasma by measuring the peak intensities of all B 6 and B 2 vitamers in 9 different lots of plasma enriched with 30 nmol/L each of PN, PNP, PL, PM, riboflavin, and FMN and 150 nmol/L each of PLP, PMP, PA, and FAD after the protein precipitation step. The increases in peak intensities of the vitamers were compared with the respective intensities measured in an aqueous calibrator solution to which the same concentrations of analytes had been added. The matrix effect was calculated as:
Peak area (added) Ϫ peak area (endogenous) Peak area (aqueous solution) ϫ 100
linearity and limits of detection
It was impossible to obtain plasma devoid of all B 6 and B 2 vitamers by dialysis, as reported previously for PLP (20 ) . We therefore prepared solutions containing 40 g/L albumin in phosphate-buffered saline, to which all vitamers were added to obtain final concentrations in the range 0.1-400 nmol/L. The albumin-phosphate-buffered saline solutions were used to assess linear ranges and limits of detection (LOD).
The signal-to-noise (S/N) ratio for each ion pair was calculated as S/N ϭ (peak height Ϫ baseline)/SD (baseline), using the S/N script supplied by Applied Biosystems (Analyst Ver. 1.3.1). LOD were determined from the linearity data as the lowest concentrations that gave peaks with S/N ratios of 5.
recovery and within-and between-day CVs
The plasma was divided into 3 portions, and to 2 of these portions we added medium (10 nmol/L each of PN, PNP, PL, PM, riboflavin, and FMN and 50 nmol/L each of PLP, PMP, PA, and FAD) and high (30 nmol/L each of PN, PNP, PL, PM, riboflavin, and FMN and 150 nmol/L each of PLP, PMP, PA, and FAD) concentrations of vitamers. We analyzed 24 replicates at each vitamin concentration (low, medium, and high) in 1 analytical run, and recovery was calculated according to the formula:
Added concentration ϫ 100
We calculated within-day precision of the assay from the data of the recovery experiments and determined the between-day precision by assaying the same samples on 22 different days over a period of 54 days.
plasma concentrations of vitamins
EDTA-plasma was collected from 94 nonfasting healthy individuals (35% male) with a median (range) age of 57 years. To study the effect of B 6 supplementation, we collected plasma from cardiovascular patients (78% male) with a median (range) age of 61 (41-76) years, who received PN (40 mg/day; n ϭ 30) or placebo (n ϭ 30) for 1 month.
Results and Discussion
We have developed a high-throughput LC-MS/MS method for the measurement of 7 vitamin B 6 and 3 vitamin B 2 species in 60 L of plasma. The sample processing and analyte extraction involved a simple protein precipitation step with an equal volume of TCA, which was carried out by a robotic workstation.
protein precipitation and liberation of the analytes
The precipitating agent (51, 52 ) and incubation time (53 ) both affect the efficiency of protein precipitation and analyte extraction. TCA is efficient in precipitating human plasma proteins (51, 52 ) . Circulating PLP is almost entirely protein bound (54 ) , and incubation of the plasma/ TCA mixture for 5 min at 50°C has been recommended to liberate all PLP (9 ) .
Storage of the plasma/TCA mixture for 10 min at room temperature, or for 60 min at 0°C, provided maximum yields of PLP, PL, and FAD but had no effect on the other vitamers. All analytes were stable during incubation. We used these experiments to establish the routine procedure for sample processing.
chromatography
The vitamers included in the assay span a wide range of chemical properties. The B 6 vitamers contain a pyridine ring, whereas all B 2 vitamers have a tricyclic isoalloxazine moiety (Fig. 1) . These structural features confer a large range of polarities and variable chromatographic behaviors on the analytes. The highly polarized B 6 species containing phosphate groups were poorly retained by the column, whereas elution of the larger B 2 species required an acetonitrile gradient.
We used a high concentration of acetic acid (650 mmol/L) to lower the pH of the mobile phase without adding TFA or other strong acids, which may suppress ionization (55 ) and thus reduce sensitivity. The mobile phase also contained HFBA, which is a volatile perfluorinated carboxylic acid suitable for LC-MS/MS (56 ) . HFBA served as a counterion and was essential for the retention of PMP on the C 8 column.
The elution profiles of plasma to which all vitamers had been added are shown in Fig. 2 , and the retention times are listed in Table 1 . In plasma from healthy persons not taking B-vitamin supplements, only PLP, PA, PL, FAD, FMN, and riboflavin were detected (Fig. 2) .
ms and acquisition settings
The mass spectrometer was used in MRM mode to optimize selectivity and sensitivity. All analytes gave a strong signal from the singly protonated molecule [MϩH] ϩ , and we selected the most abundant product ions from the fragmentograms. The selected molecular transitions are listed in Table 1 .
The parent-product ion pairs for the nonphosphorylated B 6 species suggest loss of 2 ⅐ H 2 O for PN and PA, FMN (58 ) . The product ion for FAD has the molecular mass of protonated adenylic acid (58 ) .
There was no cross-talk between ion pairs originating from different analytes or between analytes and the corresponding internal standards.
The tandem mass spectrometer allows for optimization of acquisition conditions for each analyte, and we used specific settings for each MRM transition ( Table 1 ). The mass spectrometer also permits skipping between the various MRM channels in time steps of milliseconds. To improve sensitivity, we restricted the number of parallel MRM traces to 8 by dividing each chromatographic cycle into 3 scan segments. The optimized time-scheduled MRM conditions for analyzing 10 vitamers and 3 deuterated internal standards are summarized in Table 1 .
matrix effects
The mean (SD) matrix effect for 9 different plasma lots was 32 (2)% for PMP, 114 (10)% for PLP, 16 (2)% for PNP, 106 (9)% for PA, 87 (8) for PL, 48 (9)% for PN, 81 (18)% for PM, 527 (45)% for FAD, 100 (14)% for FMN, and 121 (4)% for riboflavin. Thus, ion suppression was most pronounced for PMP and PNP, whereas substantial ion enhancement was observed for FAD. Notably, the variability, also referred to as "relative matrix effect" (49 ), was low (Ͻ10%) for most analytes.
Both ion suppression and ion enhancement occur in LC-MS/MS (49, 59 -61 ) . A substantial matrix effect may contribute to low assay precision and low reproducibility. However, adequate assay performance and analytical recovery may be obtained if the relative matrix effect is low, if the external calibrators are composed in the same matrix as the samples, and if the internal standards correct for the matrix effect. Stable-isotope internal standards should afford optimal correction because the matrix effect is expected to be the same for an analyte and its labeled analog.
internal standards
A method based on mass spectrometry allows quantification by isotope dilution with inclusion of deuterated internal standards. This is in principle the ideal strategy to correct for variability in most analytical steps from analyte extraction to detection (62 ) . We obtained 3 deuterated internal standards, d 2 -PLP, d 3 -PL, and d 8 -riboflavin, for the present assay. PMP, PLP, and PNP were corrected against d 2 -PLP, the nonphosphorylated B 6 forms against d 3 -PL, and vitamin B 2 species against d 8 -riboflavin. However, we did not observe better recovery or precision for the vitamers (PLP, PL, and riboflavin) measured with authentic deuterated standards compared with those measured in the absence of such standards (Table S-1 in  the online Data Supplement and Table 3 ).
performance of the method
We assessed assay performance in terms of linearity, sensitivity, analytical recovery, and precision.
For estimation of the linear dynamic range, we constructed calibration curves in the range 0.1-400 nmol/L (Fig. 3) . Correlation coefficients (r 2 ) Ͼ0.991 were obtained by least-square regression analysis for all compounds ( Table 2) .
LOD (defined as S/N ratio ϭ 5) were calculated for all vitamers from the linearity experiments, and the results are listed in Table 2 . LOD varied from 0.1 nmol/L for PN to 4 nmol/L for PMP and FAD. The LOD values obtained were comparable to those of other B 6 (20, 25, 27, 29 ) and B 2 (39 ) assays.
We investigated the recovery and precision of the assay by adding all vitamers at 2 (medium and high) concentrations to plasma containing endogenous vitamer concentrations.
Recoveries were in the range 78%-163% (Table S-1 of the online Data Supplement). Recoveries in the range 61%-110% have been reported for other vitamin B 6 (9, 18, 29, 63 ) and B 2 assays (39, 40 ) . Thus, recoveries that differ from 100% are a common finding. One possible explanation for this may be uneven distribution of the analytes between the protein pellet and the supernatant. This may affect the accuracy of the assay but has minor effects on precision as long as the variability is low.
The mean within-day CVs were Ͻ10% for PLP, PL, PA, and riboflavin; 10%-15% for PN, PM, FAD, and FMN; and 15%-20% for PMP and PNP (Table 3 ). The between-day CVs were in general somewhat higher than within-day CVs (Table 3) .
CVs were highest for PNP and PMP (Table 3) . These were the compounds with the highest ion suppression. Thus, the low precision could be related to the relative matrix effect, which was not totally corrected by the internal standard, d 2 -PLP.
For published B 6 assays, there are often no data on assay imprecision, or the imprecision reported varies widely, from 0.6%-5.6% (29 ), 2%-6% (9, 20 ) , and 4%-12% (27 ) , to 7%-67% (18 ) .
The precision of the vitamin B 2 measurements seems to be somewhat lower than that of our vitamin B 2 capillary electrophoresis assay (40 ) , but better than the precision reported for an HPLC assay (47 ) . stability All B 6 vitamers except PNP have been reported to be photosensitive and unstable in aqueous solutions (64 -67 ) . In plasma, PLP is unstable at room temperature (68 ) but is stable at low temperatures (Ϫ30°C) (69 ) . FAD degrades at high TCA concentrations (40 ) .
The aqueous stock solutions of vitamers; aqueous solutions of d 2 -PLP, d 3 -PL, and d 8 -riboflavin, and the EDTA-plasma used as calibrators were aliquoted and stored at Ϫ80°C. Under these conditions, we observed no degradation of the vitamers over a period of 2 years.
For protein precipitation, we chose a final TCA concentration of 25 g/L because at higher concentrations, we observed loss of FAD and a concurrent increase in FMN. After protein precipitation, the pH of the sample was ϳ1. We observed no instability for any B 6 or B 2 species in this acidic supernatant kept in subdued light at 4°C for up to 96 h (data not shown). Thus, the B 6 and B 2 vitamers are stable under the storage and sample handling conditions used for this assay.
plasma concentrations of vitamin B 6 and B 2 species
We analyzed vitamins B 6 and B 2 in 94 healthy individuals (35% male) with a mean (range) age of 57 (Table 4) . These concentrations are similar to those reported by others (9, 22, 27, 40 ) . We also analyzed samples from patients with cardiovascular disease who received vitamin B 6 (40 mg/day PN; n ϭ 30) or placebo (n ϭ 30) for 1 month and observed that PLP, PL, and PA concentrations were 10-to 100-fold higher in vitamin B 6 -supplemented patients than in the placebo group (Table 4) . This difference was of a magnitude similar to that observed in previous studies of vitamin B 6 supplementation (36, 63 ) .
No patients in the placebo group, but some patients in the B 6 group, had detectable PN (n ϭ 18) and PM (n ϭ 5). PN and PM were detected only in 3 and 5 of the healthy individuals, respectively. PNP was detected in most patients in the B 6 and placebo groups, but not in healthy persons, whereas PMP was not detected in any of the samples. Two other studies (28, 63 ) have reported the presence of PNP in plasma. PMP has been found in plasma in some (19, 25, 26, 28, 70 ) , but not all studies (18, 21, 22 ) . It is uncertain whether the presence of PMP and PNP in plasma is the result of limited hemolysis.
The B 2 concentrations were similar in the B 6 -supplemented and nonsupplemented groups.
In conclusion, the present method exploits the sensitivity and selectivity of the latest generation of tandem mass spectrometers for the measurement of all known forms of vitamins B 6 and B 2 in human plasma. The assay includes vitamers with a wide range of polarities, and the method has the advantage of high sample throughput and low sample volume requirement. The present method thus may be useful for large-scale studies of vitamins B 6 and B 2 in health and disease. 
